April 16th 2024
A new study found that Black patients with prostate cancer were less likely to get new treatments and had a higher risk of death than White patients.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
177Lu-PSMA-617 Demonstrates Significant rPFS Benefit in PSMA-Positive mCRPC
December 5th 2022In patients with PSMA-positive metastatic castration-resistant prostate cancer, the PSMA-directed therapy with 177Lu-PSMA-617, led to significant improvement in radiographic progression-free survival.
Read More
Discussing the Role of Cabazitaxel Post–Hormone Therapy for mCRPC
November 30th 2022During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants the use of cabazitaxel in a patient with metastatic castration-resistant prostate cancer who did not tolerate docetaxel.
Read More
PSMA-PET SUVmean Linked With Favorable Response to 177Lu-PSMA-617 in mCRPC
November 17th 2022Findings from the phase 2 TheraP trial showed 177Lu-PSMA-617 to result in a higher prostate-specific antigen response rate vs with cabazitaxel in patients with metastatic castration-resistant prostate cancer.
Read More
Percentage of Actionable Mutations in Prostate Cancer Underscores Importance of Testing
November 12th 2022During a presentation, Emmanuel S. Antonarakis, MD explained that homologous repair mutations and mismatch mutations in prostate cancer have therapeutic implications in the context of PARP inhibitors and PD-1 inhibitors.
Read More
Experimental Treatment With Pidnarulex and Talazoparib Starts in Patients With mCRPC
November 1st 2022Following positive results and FDA action on pidnarulex in BRAC 1/2-positive ovarian cancer, a phase 1 study is exploring the agent in metastatic castration-resistant prostate cancer, in combination with talazoparib.
Read More
Rezvilutamide Plus ADT Improves Survival in Hormone-Sensitive Prostate Cancer
October 27th 2022The phase 3 CHART study reveals better survival with rezvilutamide plus androgen deprivation therapy vs bicalutamide and androgen deprivation therapy in metastatic, hormone-sensitive prostate cancer.
Read More
Florida Cancer Specialists & Research Institute locations in Palm Beach County are now offering Pluvicto, the first targeted radioligand therapy approved by the FDA to treat an advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.
Read More
Identifying Which Patients Benefit From Cabazitaxel for mCRPC
October 7th 2022During a live virtual event, Edwin M. Posadas, MD, discussed the use of cabazitaxel in patients with metastatic castration-resistant prostate cancer with participants. This is the second of 2 articles based on this event.
Read More
Progress in Prostate Cancer Care: Highlights From a Decade of Innovation
September 27th 2022Targeted Therapies in Oncology asked some experts in prostate cancer diagnostics and therapeutics for their thoughts on the milestone improvements in treating patients with prostate cancer over the past decade.
Read More